Allergan Aesthetics Launches BOTOX® for Masseter Muscle Prominence in China

 BOTOX® Cosmetic (onabotulinumtoxinA) is the first neurotoxin approved by the China National Medical Product Administration (NMPA) to treat masseter muscle prominence (MMP) in adults. Allergan Aesthetics, an AbbVie company, announced the treatment approval on Wednesday. 

The masseter is one of the muscles in the lower face and is involved in chewing and prominence of the muscle can result in a wide and square lower face shape. 

BOTOX® for MMP offers the established dosing, robust clinical evidence and physician training that come with on-label treatment. 

"Masseter prominence is among the top aesthetics concerns for my patients and the broader Asian population, and there is a significant unmet need for minimally invasive treatment options for patients interested in addressing their lower face shape," said Professor Sun Jiaming, lead clinical study investigator and Director of the Plastic Surgery Department of Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology. "The approval of BOTOX® Cosmetic offers an effective option delivered in a single treatment dosed every six months that relaxes masseter muscles and help patients achieve a slimmer and more defined jawline." 

Allergan Aesthetics said the availability of BOTOX® for MMP in China marks another important milestone for the global aesthetic brand that medical providers and patients know and trust. 

BOTOX® Cosmetic is currently not approved by the U.S. Food and Drug Administration for MMP.